What type of study is this?

October 3, 2025BMC Pulmonary MedicineOpen Access

Efficacy and safety of Atusin® CAP in the treatment of acute uncomplicated bronchitis in the primary care setting: a multi-center, randomized, double-blind, placebo-controlled study (AABA)

View Full Paper

Ask AI

Bookmark

A clinically significant higher number of participants in the verum group achieved clinical cure compared to placebo (p = 0.029).
The mean Bronchitis Severity Scale score showed significant improvement from Day 7 (p = 0.050) until Day 10 (p = 0.011).
Participants received either Atusin CAP or placebo over 10 days in a multi-center, randomized, double-blind design, evaluating treatment impact.
The results highlight the effectiveness of Atusin CAP while showing no significant adverse events between treatment groups.

No takes yet. Share an insight, caveat, or question.

Randomized double-blind trial found Atusin CAP improved clinical cure rates in acute bronchitis patients, indicating its efficacy and safety.

Petkova et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized double-blind trial found Atusin CAP improved clinical cure rates in acute bronchitis patients, indicating its efficacy and safety.